Investment and financing strategy for the medical industry: to make a valuable second shareholder
In the current situation of China's promotion of the health care industry as a strategic industry for the country's future development, how to do a good job in investment and financing is crucial. Mr. Zeng Xiaojun, Chief Strategy Officer and Executive Partner of Gao Tejia Investment Group, said that his strategy is to make big money and be a valuable second shareholder. The core logic is to focus on the health care field, find future industry leaders, assist and grow with them. . Zeng Xiaojun: I made a comparison between Chinese and foreign medical industry investment and financing, and shared our own investment and financing concepts and logic for the industry. I. Current status of China's medical health investment In 2015, there were still many cases in the health care investment and financing situation in China. The scale of PE/VC financing has increased by 51%. The investment structure is 52% for biomedicine, 26% for pharmaceutical industry, 13% for medical equipment , and 9% for medical services. This structure is different from foreign countries. Why is this difference? Because it has a certain relationship with China and foreign market mechanisms. In terms of M&A, 623 transactions were announced, an increase of 40.87% over the same period of the previous year, and the transaction size was 24.7 billion. Actually completed 284 cases, the transaction size was 11.848 billion US dollars, up 14.71% year-on-year; The number of IPOs, 34, has increased by nearly 13.3%, and the financing scale has risen by nearly 10%. The exit case was slightly down, and the average return was also slightly reduced. In the whole of China, we have searched for relatively large M&A funds. The recent ones are not included. In fact, it seems that they are not too big. The bigger one is 10 billion, and the foreign countries are even billions or even The size of a fund of tens of billions of dollars is not the same as that of a fund. Conclusion: M&A has gradually become the mainstream, and the era of comprehensive ability has arrived! It is said that M&A is the crown jewel in the entire investment field. Because the stage of industry development has passed from simple investment and financing, in the future, in addition to giving money, it is also necessary to provide comprehensive value. The highest point is to have mergers and acquisitions and integration. The ability, so the era of comprehensive ability has come. Second, the status of global health care investment In 2015, global medical and health investment reached US$546 billion, up 34.48% year-on-year, while M&A in the range of US$50-20 billion and US$20 billion was the fastest. Large-scale mergers and acquisitions, and rapid growth, this is the general situation of investment and financing in the field of medical health in foreign countries. In 2015, globally, the number of PE transactions increased by 12%, and the amount increased by 8%. Compared with mergers and acquisitions, it seems to be a lot worse. This is also the mature stage of this market development. PE/VC may not be the starring, and may gradually become Supporting roles, industrial mergers and acquisitions become the protagonist. From 2012 to 2015, the average growth rate of medical and health investment reached 50%, which is much higher than that of other industries. 24% of corporate mergers and acquisitions and PE investment are in the range of 5-5 billion US dollars. The growth is relatively fast. Mergers and acquisitions may be played by everyone. The focus of the transaction is on medical and service services, and biomedicine in turn; domestic medicine, biomedicine, and medical devices have large structural differences. From the map on the right, this feature is found in all regions of the world, except China. There is a slight difference in the classification of the products. The first case of foreign medical health investment and financing, the first is Pfizer's acquisition of Ai Jian, 160 billion US dollars (currently unclear), the top 10 has reached 342.9 billion US dollars; China's top ten add up only 7-8 billion The US dollar, more than 40 billion yuan, this huge gap in volume also shows that the structure of the two markets is not the same. In some cases of PE, the top 10 cases are only $17 billion, which is about one-twentieth of the merger, and is mainly the investment of non-focused medical investment institutions. The number of exits was 145, an increase of 8.21%. The main exit channels were 50% for corporate mergers and acquisitions, 30% for institutional transfers, and 20% for IPOs, similar to domestic exit channels. This is the main medical fund, the scale is very large, look at the smallest is also about 6.9 billion dollars.
Endotracheal tubes are mostly made of PVC and are single-use. We provide various endotracheal tube with full sizes. Such as ETT-nasal preformed, ETT-oral preformed, ETT-with suction lumen, etc.
ENDOTRACHEAL TUBE WITH CUFF:
ENDOTRACHEAL TUBE WITHOUT CUFF :
If you are looking for endotracheal tube manufacturer, please send us an inquiry, we are glad to support you with our best price
Endotracheal Catheter,Tracheal Tube,ET Tube,Endotracheal Intubation,cuffed endotracheal tube Hangzhou Trifanz Medical Device Co., Ltd , https://www.cfzmeds.com